Plain language summary
======================

Studies have shown that hematocrit might play an important role in blood viscosity and may be an independent risk factor for stroke. Several observational studies have examined the association between hematocrit levels and the incidence of stroke; however, the findings have been inconsistent. The current findings demonstrate that higher hematocrit values were associated with a higher incidence of stroke in the Chinese population. The study also highlights how the association between hematocrit and stroke differs by gender and stroke subtype.

Introduction
============

Hematocrit is the ratio of the volume occupied by red blood cells to the volume of the whole blood. Hemoglobin concentration refers to the amount of hemoglobin per unit volume of blood. Hematocrit and hemoglobin play important roles in blood viscosity.[@b1-tcrm-14-2081],[@b2-tcrm-14-2081] Several observational studies have examined the association between hematocrit or hemoglobin levels and the incidence of stroke; however, the findings have been inconsistent.[@b3-tcrm-14-2081]--[@b9-tcrm-14-2081] The association has been investigated mainly in the Western population. Higher hematocrit levels were reported to be a risk factor for stroke in these studies, such as the Framingham Study,[@b4-tcrm-14-2081] the British Heart Study[@b5-tcrm-14-2081] and the Edinburgh Artery Study,[@b6-tcrm-14-2081] while the results of studies on Asian population are different.[@b3-tcrm-14-2081],[@b8-tcrm-14-2081] In addition, some studies have reported that the association differs by gender. For example, the REGARDS study[@b9-tcrm-14-2081] discovered a relationship between hemoglobin and stroke only among women, whereas such association was present among men in the Korean Heart Study.[@b7-tcrm-14-2081] Furthermore, the stroke is classified into three subtypes: ischemic stroke, intracerebral hemorrhage and subarachnoid hemorrhage which have different etiologies; however, few studies investigate the association between hematocrit and stroke subtypes separately.

The purpose of the current study was to investigate the association of hematocrit levels with the development of stroke and the influence of gender on this association in a Chinese population from the Kailuan cohort established in 2006.

Subjects and methods
====================

Study design and population
---------------------------

The Kailuan study is a prospective, population-based cohort study aimed at exploring the risk factors for chronic diseases (such as stroke and myocardial infarction).[@b10-tcrm-14-2081] The site of this study is the Kailuan community, a functional community of approximately 150,000 residents in Tangshan, China. The rationale, methods and examination details of the study have been previously published.[@b10-tcrm-14-2081] Overall, 101,510 individuals aged 18 years or older were enrolled between June 2006 and October 2007 in the Kailuan cohort. After exclusion of 3,669 subjects who had a history of stroke or myocardial infarction and 4,542 for whom hematocrit data were lacking, the remaining 93,299 subjects (73,926 men and 19,373 women) were enrolled in the current study ([Figure 1](#f1-tcrm-14-2081){ref-type="fig"}). Our study was approved by the ethics committee of Kailuan General Hospital. All participants signed informed consent forms and completed questionnaire interviews, physical examinations and laboratory tests.

Measurement of hematocrit
-------------------------

The element of interest was hematocrit levels measured in baseline blood samples using a Hitachi 747 automated hematology analyzer (Hitachi Ltd., Tokyo, Japan) at the central laboratory of the Kailuan General Hospital. Hematocrit is affected by circulating blood volume; hence, the blood samples were collected in the morning after an overnight fast. This method is a commonly used measurement of hematocrit in China. The normal range of hematocrit in China is 40%--50% for men and 37%--48% for women.

Assessment of potential covariates
----------------------------------

The demographic information (age, sex), lifestyle characteristics (smoking status, drinking status) and medical history (hypertension, diabetes, dyslipidemia and atrial fibrillation) were obtained using questionnaires that were conducted by professional doctors from the hospitals. Blood pressure was determined as an average of three-seated measurements using a mercury sphygmomanometer. Height and weight were measured without shoes, and body mass index (kg/m^2^) was calculated as weight divided by the square of height.

Blood samples were collected in the morning after an overnight fast and measured using a Hitachi 747 automated hematology analyzer as mentioned earlier. Fasting plasma glucose (FPG) was tested using the hexokinase/glucose-6-phosphate dehydrogenase method. Levels of triglycerides (TGs), total cholesterol (TC), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) were all measured enzymatically. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation.

As reported previously,[@b10-tcrm-14-2081]--[@b12-tcrm-14-2081] hypertension was ascertained from self-reported history of hypertension, any treatment of hypertension or SBP ≥140 mmHg or DBP ≥90 mmHg. Diabetes was ascertained from self-reported history of diabetes, any treatment of diabetes or fasting glucose level ≥7.0 mmol/L. Dyslipidemia was determined by self-reported history of dyslipidemia, any treatment of dyslipidemia or serum TG ≥1.69 mmol/L, LDL ≥3.62 mmol/L or HDL ≤1.04 mmol/L. Atrial fibrillation was ascertained from detection via electrocardiogram, self-reported history of atrial fibrillation or any treatment of atrial fibrillation.

Follow-up and outcome assessment
--------------------------------

The participants were followed up by trained physicians or nurses until December 31, 2015. The outcomes of interest were mainly collected through face-to-face interviews at health examinations every 2 years. As for participants who did not attend the routine health examination ([Table S1](#SD1-tcrm-14-2081){ref-type="supplementary-material"}), the outcome information was obtained by checking medical insurance records and death certificates from provincial vital statistics offices. Then, the outcome information was validated by reviewing the medical records from the 11 local hospitals.

The primary outcome was the first occurrence of stroke, which was diagnosed based on a combination of symptoms of neurological deficits and brain computed tomography or magnetic resonance imaging according to the WHO criteria.[@b13-tcrm-14-2081] All stroke events were established by the Arbitration Committee for Clinical Outcomes and the Data Safety Monitoring Board. The outcomes were classified into three subtypes: ischemic stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Because of the low incidence of subarachnoid hemorrhage, we excluded patients with subarachnoid hemorrhage from the following analyses.

Statistical analyses
--------------------

Given the differences in the distribution of hematocrit values by sex, the subjects were classified into five groups according to sex-specific quartiles of hematocrit levels. Male and female participants were divided into five quintiles separately according to hematocrit. The five quintiles (Q1--Q5) of the total population were composed of the corresponding parts of male and female participants (men: Q1, \<41.5%; Q2, 41.6%--44.0%; Q3, 44.0%--45.9%; Q4, 46.0%--48.5%; and Q5, \>48.6%; women: Q1, \<36.6%; Q2, 36.7%--38.8%; Q3, 38.9%--40.7%; Q4, 40.7%--43.1%; and Q5, \>43.2%). Descriptive statistics were used to present the participant characteristics across the quartiles of baseline hematocrit values. The continuous variables are described by mean and SD, and the categorical variables are described by percentages. A test for linear trend was performed to determine the trends of characteristics within the hematocrit quartiles.

Cox proportional hazards analysis was used to examine the associations of baseline hematocrit levels with the incidences of stroke, ischemic stroke and hemorrhagic stroke by treating the lowest quartile as the reference in sequential models. The choice of adjusted factors was mainly based on two considerations which on the one hand was from the statistically significant factors of test for linear trend and on the other hand was from the factors reported in the literature that have an impact on stroke. Model 1 was adjusted for age and sex. Model 2 was adjusted for variables in model 1 plus body mass index, smoking, drinking, dyslipidemia, diabetes mellitus and hypertension. Model 3 was adjusted for variables in model 2 plus atrial fibrillation, SBP, FPG, TC, LDL and eGFR. In addition, a test for linear trend was performed for each model. Further, we conducted a sensitivity analysis to test the robustness of our findings. Hypertension is an important risk factor for stroke, and some people developed hypertension during the follow-up period. So, we repeated our analysis after excluding these individuals. Finally, because previous studies showed that the association of hematocrit with stroke was modified by sex,[@b3-tcrm-14-2081],[@b7-tcrm-14-2081],[@b9-tcrm-14-2081] we tested whether there was an interaction of sex and baseline hematocrit levels (hematocrit × sex). Two-sided *P*-values are reported for all analyses. A value of *P*\<0.05 was considered to be statistically significant. All statistical analyses were performed by SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA).

Results
=======

In the current study, men composed 79.24% of the entire population. The mean values of hematocrit were 45.1% for men and 40.0% for women. During a mean follow-up of 8.85±1.03 years, 2,881 participants had ischemic stroke and 743 had hemorrhagic stroke ([Figure 1](#f1-tcrm-14-2081){ref-type="fig"}). The baseline characteristics of the study population according to the quartiles of hematocrit values are summarized in [Table 1](#t1-tcrm-14-2081){ref-type="table"}. When compared with the participants with lower hematocrit levels, the individuals with higher hematocrit levels were more likely to be younger, had a lower eGFR level, had higher prevalences of smoking and drinking, hypertension, diabetes mellitus and dyslipidemia and had higher SBP, DBP, BMI, TG, LDL and TC levels.

[Table 2](#t2-tcrm-14-2081){ref-type="table"} summarizes the HRs with 95% CIs for stroke and its subtypes according to the hematocrit quartiles and *P*-values from the models. There was no significant association between hematocrit and stroke in the unadjusted model. However, in the multivariate-adjusted analyses, the hematocrit levels were positively correlated with the incidence of total stroke (*P*\<0.01 for all). Compared with the first hematocrit quartile as a reference, the highest quartile had a significantly higher age- and sex-adjusted incidence of stroke in model 1 (HR 1.50, 95% CI 1.34--1.67). After adjusting for the demographic factors and laboratory indices in model 2 and model 3, the association between hematocrit and stroke incidence was attenuated but remained significant. The adjusted HR (95% CI) for stroke in model 2 was 1.25 (1.12--1.39) and 1.17 (1.04--1.31) in model 3. In the sensitivity analysis, the associations remained significant after excluding individuals who developed hypertension during the follow-up (HR 1.17, 95% CI 1.04--1.31). In terms of the subtypes of stroke, the incidence of ischemic stroke was increased significantly in the highest quartile in the three models. However, no significant association was observed with the incidence of hemorrhagic stroke.

There were no statistical interactions between the hematocrit and sex. However, sex-specific analyses were carried out for the sake of interest, because the normal ranges of hematocrit are generally higher in men than in women. As shown in [Figure 2](#f2-tcrm-14-2081){ref-type="fig"}, the relationship between hematocrit and stroke exhibits gender differences. As in the total population, the hematocrit levels were also linearly correlated with the incidence of stroke in men (model 3: HR 1.20, 95% CI 1.07--1.35, *P* for trend \<0.001), but there was no significant association between hematocrit and stroke in women.

Discussion
==========

Using the data from a long follow-up of the Kailuan community, we found that the incidence of stroke was significantly increased in subjects with higher hematocrit levels and this association was mainly found among ischemic stroke subtype and male participants. These findings emphasize the clinical importance of high hematocrit level as a risk factor for stroke in the Chinese population.

Previous studies have highlighted the association between hematocrit and stroke incidence. Gagnon et al[@b4-tcrm-14-2081] examined this association in the Framingham cohort. Their results revealed that hematocrit was an important risk factor for some cardiovascular events, but the hematocrit produced different effect on stroke events of different age and sex groups. Later, two follow-up studies, one from the British Heart Study[@b5-tcrm-14-2081] and one from the Edinburgh Artery Study,[@b6-tcrm-14-2081] reported that high hematocrit levels were associated with a higher incidence of stroke, which is similar to our finding. In addition, some studies also found that a higher level of hematocrit was an independent risk factor for other vascular diseases, such as ischemic heart disease[@b14-tcrm-14-2081] and venous thromboembolism,[@b15-tcrm-14-2081],[@b16-tcrm-14-2081] which echo the association between hematocrit and stroke. Therefore, our study adds to this literature by showing the linear association between hematocrit and stroke incidence. There were also some studies that presented different views. For example, a Japanese study from the Hisayama cohort by Kiyohara et al[@b3-tcrm-14-2081] found that lower hematocrit levels will increase the incidence of ischemic stroke. However, fewer events occurred in this study, so the level of evidence is weak. In the same cohort, another study published in 2015 by Gotoh et al[@b8-tcrm-14-2081] showed that higher hematocrit levels increased the incidence of ischemic stroke, which is in agreement with our study. However, lower hematocrit levels were considered to be a risk factor for hemorrhagic stroke in Gotoh et al's study, while in our study, there was no significant relationship between lower hematocrit and hemorrhagic stroke. This difference could be explained partially by the study population, as the mean hematocrit values and the incidence of hemorrhagic stroke in our study were lower than those in the Japanese study.

Several pathophysiological mechanisms could potentially explain the association of high hematocrit levels with an increased ischemic stroke incidence. Elevated hematocrit levels lead to increased blood viscosity and peripheral resistance, thereby reducing cerebral circulation.[@b1-tcrm-14-2081],[@b2-tcrm-14-2081],[@b17-tcrm-14-2081] In addition, high hematocrit levels increase peripheral platelet activation by releasing erythrocyte-derived ADP.[@b18-tcrm-14-2081],[@b19-tcrm-14-2081] Increased hematocrit levels may also contribute to developing ischemic stroke by other mechanisms, such as oxidative stress, lipid peroxidation[@b20-tcrm-14-2081] and thrombin generation.[@b21-tcrm-14-2081],[@b22-tcrm-14-2081] The mechanism why high hematocrit levels increased intracerebral hemorrhage incidence is unclear. Some studies have reported that high hematocrit levels are associated with the onset of hypertension. In addition, hypertension is a significant risk factor for hemorrhagic stroke, so high hematocrit levels may affect intracerebral hemorrhage by blood pressure.

The differential associations of hematocrit and stroke incidence with sexes could be explained by the different hematocrit distribution between men and women. The mean hematocrit level of the fifth quartile in men was higher than that in women (46.3% for women vs 51.6% for men, *P*\<0.001). In addition, age-specific stroke rates are higher in men than women. Adult males have a higher stroke incidence than age-matched females.[@b23-tcrm-14-2081],[@b24-tcrm-14-2081] Because of declining estrogen levels, the risk of stroke in women increases after menopause, but women also have lower stroke rates than men. Therefore, the hematocrit level of most women might not be high enough to contribute to stroke.

The strengths of our study include the prospective study design, a large study sample size in the Chinese population, a long follow-up period and an accurate method for stroke diagnosis through reviewing medical records. However, some limitations of our study should be mentioned. First, our findings were based on baseline hematocrit measurements. However, the hematocrit levels may change during the follow-up period, so we cannot determine whether any changes in hematocrit levels were associated with stroke incidence. Second, although we attempted to account for possible confounding factors, residual confounders might still exist in our analysis such as anticoagulants and antiplatelets. However, we could not collect this information because Kailuan database did not include them. Next, most participants of the Kailuan study are male coal miners, so the study population might not represent the general Chinese population. In addition, because our findings are based on an observational study design, we cannot make definite causal inferences between high hematocrit levels and stoke incidence.

Conclusion
==========

Our findings suggest that higher hematocrit levels are associated with a higher incidence of stroke in the Chinese population and the influence of hematocrit is mainly in ischemic stroke. The hematocrit levels should be taken into consideration when assessing the incidence of stroke.

Supplementary material
======================

###### 

Number of participants who did not undergo the routine health examination

                         2008--2009   2010--2011   2012--2013   2014--2015
  ---------------------- ------------ ------------ ------------ ------------
                                                                
  Absent number (n)      22,031       26,721       25,549       32,185
  Cumulative death (n)   581          1,866        3,609        5,427
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###### 

Baseline characteristics of study participants by quartiles of hematocrit

                               Hematocrit Q1    Hematocrit Q2    Hematocrit Q3    Hematocrit Q4    Hematocrit Q5    *P* for trend
  ---------------------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------
                                                                                                                    
  N                            18,447           18,503           18,611           19,190           18,548           
  Age, years                   55.21±13.21      52.53±12.33      51.16±12.08      50.20±12.09      48.83±12.09      \<0.001
  Men, n (%)                   14,613 (79.22)   14,542 (78.56)   14,716 (79.07)   15,426 (80.39)   14,629 (78.87)   0.23
  Current smoking, n (%)       4,918 (26.22)    5,723 (30.93)    6,082 (32.68)    6,742 (35.13)    7,034 (37.92)    \<0.001
  Current drinking, n (%)      5,346 (28.98)    6,137 (33.17)    6,662 (35.80)    7,242 (37.74)    7,846 (42.43)    \<0.001
  Body mass index, kg/m^2^     24.28±3.54       24.76±3.45       25.08±3.44       25.34±3.42       25.66±3.47       \<0.001
  Hypertension, n (%)          7,552 (40.94)    7,846 (42.40)    8,090 (43.47)    8,739 (45.54)    8,307 (44.79)    \<0.001
  Diabetes mellitus, n (%)     1,425 (7.72)     1,593 (8.61)     1,569 (8.43)     1,892 (9.86)     1,940 (10.46)    \<0.001
  Dyslipidemia, n (%)          5,641 (30.58)    6,178 (33.39)    6,512 (34.99)    6,956 (36.25)    6,890 (37.15)    \<0.001
  Atrial fibrillation, n (%)   89 (0.48)        68 (0.37)        69 (0.37)        82 (0.43)        90 (0.49)        0.66
  SBP, mmHg                    129.98±21.12     130.45±20.71     130.77±20.51     131.56±20.80     131.19±21.13     \<0.001
  DBP, mmHg                    81.64±11.51      83.05±11.56      83.64±11.53      84.43±11.82      84.53±12.12      \<0.001
  FPG, mmol/L                  5.32±1.58        5.42±1.63        5.44±1.57        5.55±1.78        5.55±1.80        \<0.001
  TC, mmol/L                   4.77±1.14        4.87±1.14        4.94±1.15        5.03±1.14        5.08±1.15        \<0.001
  LDL, mmol/L                  2.15±1.03        2.29±0.97        2.38±0.92        2.44±0.86        2.42±0.78        \<0.001
  HDL, mmol/L                  1.57±0.43        1.54±0.41        1.54±0.41        1.55±0.39        1.57±0.39        0.58
  TGs, mmol/L                  1.54±1.35        1.63±1.40        1.69±1.39        1.75±1.39        1.76±1.37        \<0.001
  EGFR, mL/min per 1.73 m^2^   82.87±29.74      83.18±25.22      82.43±23.25      81.39±25.92      79.37±24.30      \<0.001

**Notes:** Hematocrit levels were classified into sex-specific quartiles (men: Q1, \<41.5%; Q2, 41.6%--44.0%; Q3, 44.0%--45.9%; Q4, 46.0%--48.5%; and Q5, \>48.6%; women: Q1, \<36.6%; Q2, 36.7%--38.8%; Q3, 38.9%--40.7%; Q4, 40.7%--43.1%; and Q5, \>43.2%).

**Abbreviations:** EGFR, EGF receptor; FPG, fasting plasma glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TC, total cholesterol; TG, triglyceride; Q, quintile.

###### 

HRs (95% CI) of incident stroke according to quartiles of baseline hematocrit

                                                                         Q1               Q2                      Q3                      Q4                      Q5                      *P* for trend
  ---------------------------------------------------------------------- ---------------- ----------------------- ----------------------- ----------------------- ----------------------- ---------------
                                                                                                                                                                                          
  **Stroke, n (%)**                                                      **747 (4.05)**   **709 (3.83)**          **694 (3.73)**          **751 (3.91)**          **706 (3.81)**          
  Crude HR (95% CI)                                                      1.0              0.99 (0.89--1.10)       1.00 (0.90--1.11)       1.08 (0.97--1.20)       1.07 (0.96--1.19)       0.08
  Model 1 HR[a](#tfn3-tcrm-14-2081){ref-type="table-fn"} (95% CI)        1.0              1.16 (1.04--1.28)       1.25 (1.12--1.39)       1.40 (1.26--1.55)       1.50 (1.34--1.67)       \<0.001
  Model 2 HR[b](#tfn4-tcrm-14-2081){ref-type="table-fn"} (95% CI)        1.0              1.08 (0.97--1.20)       1.13 (1.01--1.25)       1.21 (1.09--1.35)       1.25 (1.12--1.39)       \<0.001
  Model 3 HR[c](#tfn5-tcrm-14-2081){ref-type="table-fn"} (95% CI)        1.0              1.05 (0.95--1.17)       1.09 (0.98--1.21)       1.16 (1.04--1.29)       1.17 (1.04--1.31)       0.0016
  **Ischemic stroke, n (%)**                                             **582 (3.15)**   **563 (3.04)**          **557 (2.99)**          **625 (3.26)**          **554 (2.99)**          
  Crude HR (95% CI)                                                      1.0              1.01 (0.90--1.32)       1.03 (0.92--1.16)       1.16 (1.03--1.30)       1.08 (0.95--1.22)       0.04
  Model 1 HR[a](#tfn3-tcrm-14-2081){ref-type="table-fn"} (95% CI)        1.0              1.19 (1.06--1.34)       1.31 (1.16--1.47)       1.53 (1.36--1.72)       1.54 (1.36--1.75)       \<0.001
  Model 2 HR[b](#tfn4-tcrm-14-2081){ref-type="table-fn"} (95% CI)        1.0              1.11 (0.99--1.25)       1.18 (1.05--1.33)       1.32 (1.17--1.48)       1.28 (1.13--1.45)       \<0.001
  Model 3 HR[c](#tfn5-tcrm-14-2081){ref-type="table-fn"} (95% CI)        1.0              1.09 (0.96--1.22)       1.14 (1.01--1.28)       1.25 (1.11--1.41)       1.19 (1.05--1.35)       \<0.001
  **Intracerebral hemorrhage, n (%)**                                    **170 (0.92)**   **143 (0.77)**          **143 (0.77)**          **140 (0.73)**          **147 (0.79)**          
  Crude HR (95% CI)                                                      1.0              0.88 (0.70--1.10)       0.90 (0.72--1.12)       0.87 (0.69--1.10)       1.00 (0.79--1.26)       0.88
  Model 1 HR[a](#tfn3-tcrm-14-2081){ref-type="table-fn"} (95% CI)        1.0              0.99 (0.79--1.24)       1.07 (0.85--1.34)       1.07 (0.85--1.35)       1.30 (1.03--1.64)       0.04
  Model 2 HR[b](#tfn4-tcrm-14-2081){ref-type="table-fn"} (95% CI)        1.0              0.93 (0.75--1.17)       0.97 (0.77--1.22)       0.94 (0.75--1.19)       1.11 (0.87--1.41)       0.49
  Model 3 HR[c](#tfn5-tcrm-14-2081){ref-type="table-fn"} (95% CI)        1.0              0.93 (0.74--1.16)       0.96 (0.76--1.21)       0.93 (0.73--1.17)       1.08 (0.85--1.38)       0.61
  **Sensitivity analysis[d](#tfn6-tcrm-14-2081){ref-type="table-fn"}**   **1.0**          **1.05 (0.94--1.16)**   **1.10 (0.99--1.23)**   **1.17 (1.05--1.30)**   **1.17 (1.04--1.31)**   **0.0011**

**Notes:**

Model 1: adjusted for age and sex.

Model 2: adjusted for age, sex, smoking, drinking, body mass index, hypertension, diabetes mellitus and dyslipidemia.

Model 3: adjusted for age, sex, smoking, drinking, body mass index, hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, SBP, FPG, TC, LDL and estimated glomerular and proteinuria.

Adjusted for model 3 and further excluded individuals who developed hypertension during the follow-up.

**Abbreviations:** FPG, fasting plasma glucose; LDL, low-density lipoprotein; TC, total cholesterol; Q, quintile.
